Patient Treatment Date/time: Diagnosis: Treatment Regimen:

Similar documents
PREOPERATIVE ANAEMIA PATHWAY

T: N: M: EORTC SYSTEMIC THERAPY CHECKLIST. Protocol number: SeqID. Copyright EORTC August 2007 COMPARATIVE PERFORMANCE STATUS TABLE

Supplementary Appendix

For the Patient: HNAVFUP Treatment for Advanced Squamous Cell Cancer of the Head and Neck using Fluorouracil and Platinum

For the Patient: Rituximab injection Other names: RITUXAN

For the Patient: USMAVFIPI

SCALES SCALES SCALES. Performance Scales WHAT SHOULD THE RAINBOW FISH DO WITH ALL OF THESE SCALES?? KPS FAST ECOG PPS NYHA MRI ALSFRS

For the Patient: Mitoxantrone Other names:

For the Patient: Amsacrine Other names: AMSA PD

Eloxatin Oxaliplatin concentrated solution for injection

For the Patient: Paclitaxel Other names: TAXOL

Edinburgh Cancer Centre, Western General Hospital. Understanding Epirubicin, Oxaliplatin & 5-Fluorouracil Chemotherapy (EOF)

NURSING PROCESS FOCUS: Patients Receiving Amphotericin B (Fungizone, Abelcet)

Management of the complications of myeloma and side-effects of treatment Christine Morris Clinical Nurse Specialist in Myeloma Royal Derby Hospital

Patient Information IXEMPRA Kit (pronounced as ǐk-'sĕm-pră) (ixabepilone) What is the most important information I should know about IXEMPRA?

Docetaxel (Taxotere )

For the Patient: Cyclosporine injection Other names: SANDIMMUNE I.V.

For the Patient: Bendamustine Other names: TREANDA

2. Have your symptoms affected your ability to carry out your daily activities? YES NO

Docetaxel (Taxotere) with GCSF

VIDE. Vincristine given via intravenous (IV) infusion over 10 minutes Etoposide & doxorubicin given together via IV infusion over 4 hours

For the Patient: GOOVDDCAT

YOUR GUIDE TO TECENTRIQ (atezolizumab) non-small cell lung cancer (NSCLC)

For the Patient: GOOVCATM

For the Patient: GOOVCATR

ABOUT THIS MEDICATION What is this drug used for? Gemcitabine is an intravenous anticancer medication used for some types of cancer.

ABOUT THIS MEDICATION

Myeloma Haematology and Transplant Unit

Discussing TECENTRIQ (atezolizumab) with your healthcare team

Spinal Anaesthesia and Analgesia. Patient information Leaflet

For the Patient: GIPAJGEM Other Names: Adjuvant chemotherapy for pancreatic cancer using Gemcitabine

For the Patient: Trastuzumab emtansine Other names: KADCYLA

For the Patient: Fludarabine injection Other names: FLUDARA

For the Patient: Eribulin Other names: HALAVEN

For the Patient: USMAVPEM

For the Patient: GIPGEM Other Names: Metastatic cancer of the pancreas, gallbladder or bile duct.

PART III: CONSUMER INFORMATION

For the Patient: ULUAVPMTN

Nivolumab. Other Names: Opdivo. About this Drug. Possible Side Effects (More Common) Warnings and Precautions

For the Patient: GIAVPANI Other Names: Palliative third line treatment of metastatic cancer of the colon or rectum using Panitumumab

Prof A Pourazar Immunohematologist

For the Patient: LUAJPC

VDC IE. Your treatment You will have 14 cycles of VDC IE given every 2 to 3 weeks.

Cisplatin and Capecitabine

For the Patient: Ponatinib Other names: ICLUSIG

The treatment is given every 3 weeks for 6 to 8 cycles.

For the Patient: GUBEP

Breast Pathway Group Docetaxel in Advanced Breast Cancer

Obinutuzumab (lymphoma) Obinutuzumab (lymphoma)

What are these drugs used for? Paclitaxel and carboplatin are intravenous anticancer medications used for many types of cancer.

Understanding your HICKMAN CATHETER

Supplementary Online Content

New Patient History. Name: DOB: Sex: Date: If yes, give the name of the physician who did your evaluation or ordered your tests:

GCVP. Cyclophosphamide by injection Vincristine by short infusion. Gemcitabine by infusion over 30 minutes

5 Fluorouracil. Other Names: Adrucil. About This Drug. Possible Side Effects. Fluorouracil is used to treat cancer.it is given in the vein (IV).

Nivolumab. Nivolumab

Dexamethasone is used to treat cancer. This drug can be given in the vein (IV), by mouth, or as an eye drop.

Lung Pathway Group Docetaxel & Carboplatin in Non- Small Cell Lung Cancer (NSCLC)

Amarillo Surgical Group Doctor: Date:

Maternity Services Intravenous iron therapy Information for women

For the Patient: USMAVNIV

Pain relief after major surgery

ABOUT THIS MEDICATION

Gemcitabine and Cisplatin (urology)

For the Patient: Neoadjuvant therapy for locally advanced breast cancer using weekly paclitaxel followed by doxorubicin and cyclophosphamide

Pain Management Questionnaire

PREOPERATIVE ANAEMIA PATHWAY

For the Patient: ULUAVPMB

Breast Pathway Group TC (Docetaxel / Cyclophosphamide) in Early Breast Cancer

For the Patient: Protocol LUAJNP Other names: Adjuvant Treatment of Non-Small Cell Lung Cancer with Cisplatin and Vinorelbine

For the Patient: LUAVPP

For the Patient: GIAVPG Other Names: First-line palliative chemotherapy for advanced gallbladder and bile duct cancer using Gemcitabine and Cisplatin

Myeloma Haematology and Transplant Unit CTD1

YOUR OPERATION EXPLAINED

For the Patient: Adjuvant therapy for breast cancer using weekly paclitaxel and trastuzumab (Herceptin)

Nilotinib (nil ot' i nib) is a drug that is used to treat some types of cancer. It is a capsule that you take by mouth.

Paclitaxel (Taxol) and carboplatin

For the Patient: Olaparib tablets Other names: LYNPARZA

Haematology. The other 2 drugs, folinic acid and GCSF, help to reduce the side effects of the treatment.

How is this regimen given? Are there other medications I will receive with this regimen? What side effects can occur with this regimen?

Medical History Form

For the Patient: ACTW Other names: BRAJACTW

Discussing TECENTRIQ (atezolizumab) with your healthcare team Talking to Your Doctor

For the Patient: LUAVPG

For the Patient: ACD

What is the most important information I should know about bortezomib? What should I discuss with my healthcare provider before receiving bortezomib?

STEP 1: Forms Please complete all the attached forms and bring them with you on the day of your visit.

Brentuximab vedotin. Brentuximab vedotin

ABVD. by infusion over 30 minutes. You will have treatment on Day 1 and Day 15 (this is one cycle) for 2, 3 or 6 cycles.

Paclitaxel (Taxol) Paclitaxel is given into the vein (intravenously) through a fine tube (cannula) as an infusion over 1 hour.

VELCADE Powder for Injection Bortezomib3.5 mg and 1 mg

HD CLINIC MEDICAL HISTORY FORM

INTRAVENOUS IRON THERAPY

Transarterial Chemoembolization (TACE)

Your CODOX-M / IVAC treatment. Information for patients Specialised Medicine

ABOUT THIS MEDICATION What are these drugs used for? Docetaxel is an anticancer drug used to treat cancers in the area of the neck and throat.

PAEDIATRIC FEBRILE NEUTROPENIA CARE PATHWAY

Myeloma Haematology and Transplant Unit MPT

Transcription:

Name: Address: DOB: HCRN: Consultant: Ward: Assessment: Pre Systematic Anti Cancer Therapy (SACT) Continuation *This assessment is for patients on multiday regimens Patient Treatment Date/time: Diagnosis: Treatment Regimen: Cycle number: Cycle day: Vital Signs/Early Warning Score completed NA Have all necessary bloods been completed? FBC U&E Liver profile Bone profile Coagulation Screen Iron Studies TFTs CRP Other Details: Tumour markers Details: Blood results reviewed and satisfactory to proceed with treatment? Details: Peripheral Intravenous Cannulation (PIVC) Record How many attempts to successfully cannulate: Time/date Size of PIVC Vein 1 Blood return VIPs score 1 Patient tolerance of procedure achieved 2 Initial/NMBI pin 1 See appendix 1 and indicate if the right or left arm used 2 If no or poor blood return achieved, please document action in nursing note

Patient Name DOB HCrN Central Venous Access Device (CVAD) Record PICC Port Hickman Vascath Other Details: Time/Date Lumen Blood return Lumens flushed and Catheter external Description of exit site colour achieved? 3 patent? 3 length (if applicable) Red Blue Yellow Brown Red Blue Yellow Brown Red Blue Yellow Brown initial/nmbi Pin Pre treatment checks CTCAE Version 4 4 Grade CTCAE Version 4 Grade Chest pain Weight loss Infection Diarrhoea Bleeding Constipation Dyspnoea Urinary disorder Confusion/cognitive disturbance Fatigue Pain Peripheral neuropathy -sensory Mood alteration Peripheral neuropathy -motor Mucositis/stomatitis Bruising Nausea Rash Vomiting Occular/Eye problems Anorexia Palmer/Planter Syndrome Other ECOG Status 5 SACT Administration Blood return present prior to commencing and throughout treatment? SACT fully infused without any adverse events If ambulatory SACT pump attached correctly? NA If ambulatory SACT pump attached, is clamp open? NA Assessment completed by: NMBI pin: Please document additional details in notes section if required 3 If No, document further actions in nurses notes section 4 See appendix 2 for CTCAE version 4 5 See appendix 3 for ECOG score

Patient Name DOB HCrN Does the patient require admission? Has PIVC been flushed & removed? Any PIVC complications? CVAD flushed as per hospital policy? Any CVAD complications? Has Huber needle been removed? (if applicable) Discharge Location: NA Time PIVC removed: Comments: NA Comments: NA Comments: If 5fu pump attached on discharge, has disconnection been arranged? Has spill kit been given to patient (If applicable) Safe handling and disposal of cytotoxic drug information leaflet given? Date given for CVAD flush and dressing if not for treatment before next due? NA Give details of disconnection: Time: Date: Location: Day ward CIT NA Yes No NA Is the Patient for any supportive medications at home? Did the patient receive a prescription? Details: NA Give details of flush/dressing Time: Date: Location: Day ward CIT PHN If the patient is for G-CSF, is administration arranged? NA Details: MDT referrals/community supports arranged this visit Is patient for follow up/review appointment? NA Has the appointment been arranged? NA Details: Have blood requests for next appointment been given to patient? NA Details: Next day ward appointment date: Next appointment time: Reason: Assessment completed by NMBI pin

Patient Name DOB HCrN Time Notes Sign/NMBI Signature Bank Name Signature Initials Role NMBI Pin

Appendix 1: Visual Infusion Score (VIPS) Visual Infusion Phlebitis Score (VIPS) Condition of site Score IV site appears healthy 0 One of the following is evident: 1 Slight pain near IV site Slight redness near IV site Two of the following are 2 evident: Pain at IV site Erythema Swelling Appendix 2: Common Terminology Criteria for Adverse Events- CTCAE Version 4 Grades Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 Chest pain Location? When did it start? Mild Pain pain; limiting instrumental Pain at rest; Infection Has the patient taken their own temp? Any chills, shivering, shaking episodes? Any local signs? Are they neutropenic? Dyspnoea It is a new symptom? Is it worsening? Any chest pain and for how long? *consider SVCO, anemia, treatment related Confusion/cogniti ve disturbance Is this symptom new? How long have they had these symptoms? Is it getting worse? Any s to medications? Pain Is it a new symptom? How long? Is the pain constant? or no or no or no Asymptomatic or mild symptoms not requiring intervention New onset shortness of breath with moderate exertion Mild disorientation not interfering with s. Slight decrease in level of alertness Mild pain: not interfering with function Localised. Localised intervention indicated Shortness of breath with minimal exertion; limiting instrumental cognitive disability and/or disorientation limiting s pain: pain or analgesia not activities of daily living Intravenous antibiotics indicated Shortness of breath at rest; Severe cognitive disability and/or severe confusion; severely limiting s. Altered level of consciousness Severe pain: Pain or analgesia s Death consequences, loss of consciousness Disabling

Grades Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 Mood alteration How long have they felt this way? What help them feel better? What supports are in place? Mild mood alteration, not function mood alteration, not s Severe mood alteration s Mucositis/Stomati tis Are there mouth ulcers? Evidence of infection? Able to eat and drink? Asymptomatic or mild symptoms pain not interfering with oral intake Severe pain, oral intake Suicidal ideation Danger to self or others Requires parentrenal/entren al support Nausea What is their oral intake like? Are they taking antiemetic? Vomiting How many days/episodes? Are they constipated or have diarhorea? Loss of appetite without alteration in eating habits 1-2 episodes in 24 hours Oral intake decrease without significant weight loss or dehydration 3-5 episodes in 24 hours Inadequate oral caloric and fluid intake >6 episodes in 24 hours consequences Anorexia What is appetite like? Has it recently d? Weight loss Are they trying to lose weight? Diarrhoea *Consider infection Constipation How many days since LBM? What s their baseline? Any nausea, vomiting or abdominal pain? Urinary frequency Fatigue Any other associated symptoms? or no Loss of appetite without to eating habits 5-10% less than baseline Increase of <4 stools per day over baseline. Mild increase in ostomy output Occasional or intermittent symptoms, occasional use of laxatives Nocturia or increase x 2 times function Mild: Increase in baseline fatigue, but not effecting daily activities Oral intake altered without significant weight loss or malnutrition 10-20% less than baseline Increase of 4-6 stools per day over baseline. increase in ostomy output Persistent symptoms with regular use of laxatives/ene mas and limited s (activities of daily living) Increase>2 times x <hourly : Decrease in performance and difficulties with s and Oral intake altered in association with significant weight loss/malnutrition >20% less than baseline Increase of >7 stools per day over baseline Severe increase in ostomy output Constipation >1 hourly urgencycatheter indicated Severe Significant decrease in performance and interferes with ALDs complications such as collapse consequences Obstruction/Life threatening consequences Disabling

Grades Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 Peripheral Neuropathy When did it start? Is it continuous? Is it getting worse or affecting mobility or function? Any constipation or urinary incontinence? Asymptomatic parenthesis/tingl ing persistent. Not interfering with s Sensory alteration, Interferes with not s Sensory alteration, Interferes with s Disabling Permanent sensory loss *consider spinal cord compression Bruising Localized or in a dependent area Rash Macules/papule Is it localized or s covering < generalized? 10% BSA with How long has it or without been there? symptoms (e.g., Signs of infection? pruritus, Is there any itch? burning, tightness) Nail Changes When did it start? How long has it been there? or no Discolored, ridging, pitting Generalized Macules/papul es covering 10-30% BSA with or without symptoms (e.g., pruritus, burning, tightness); limiting instrumental Partial or complete nail loss Macules/papule s covering >30% BSA with or without associated symptoms; Interferes with s Palmer/planter syndrome Mild numbness, tingling swelling of hands and feet with or without pain or redness Painful redness and/or swelling of the hands and/or feet Moist desquamation, ulceration and severe pain Appendix 3: ECOG Status ECOG Status ECOG score 0 ECOG score 1 ECOG score 2 ECOG score 3 ECOG score 4 Fully active, able to carry on all predisease performance without restriction Capable of only limited self care, confined to bed or chair more than 50% of waking Completely disabled Cannot carry on any self- care. Totally confined to bed or chair hours Restricted in physically strenuous activity but ambulatory and able to carry out work of light or sedentary nature, e.g. light house work, office work Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% or waking hours Oken M, Creech R, Tormey D, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group.Am J Clin Oncol. 1982;5:649-655.